Disclosures for "Vortioxetine Improves Cognition and Quality of Life in Racially and Ethnically Minoritized Individuals With Post-COVID-19 Condition: A Randomized, Double-blind, Placebo-controlled Trial"
-
Miss Kwan has nothing to disclose.
-
Mr. Lakhani has nothing to disclose.
-
Roger McIntyre has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Roger McIntyre has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Roger McIntyre has received personal compensation in the range of $5,000-$9,999 for serving as a Research Grant Support with CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute.